作者：
Aditya,Bardia [1]
;
Xichun,Hu [1]
;
Rebecca,Dent [1]
;
Kan,Yonemori [1]
;
Carlos H,Barrios [1]
;
Joyce A,O'Shaughnessy [1]
;
Hans,Wildiers [1]
;
Jean-Yves,Pierga [1]
;
Qingyuan,Zhang [1]
;
Cristina,Saura [1]
;
Laura,Biganzoli [1]
;
Joohyuk,Sohn [1]
;
Seock-Ah,Im [1]
;
Christelle,Lévy [1]
;
William,Jacot [1]
;
Natasha,Begbie [1]
;
Jun,Ke [1]
;
Gargi,Patel [1]
;
Giuseppe,Curigliano [1]
;
DESTINY-Breast06 Trial Investigators
作者单位：
From Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, and Massachusetts General Hospital, Boston, MA (A.B.); the Department of Medical Oncology, Fudan University Shanghai Cancer Center, and the Department of Oncology, Shanghai Medical College, Fudan University, Shanghai (X.H.), and Harbin Medical University Cancer Hospital, Harbin (Q.Z.) - all in China; the Division of Medical Oncology, National Cancer Center Singapore, Singapore (R.D.); National Cancer Center Hospital, Tokyo (K.Y.); the Latin American Cooperative Oncology Group, Porto Alegre, Brazil (C.H.B.); Texas Oncology and US Oncology, Baylor University Medical Center, Dallas (J.A.O.); the Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium (H.W.); the Department of Medical Oncology, Institut Curie and Université Paris Cité, Paris (J.-Y.P.), Centre François Baclesse, Caen (C.L.), and the Department of Medical Oncology, Institut du Cancer de Montpellier, Université de Montpellier, INSERM Unité 1194, Montpellier (W.J.) - all in France; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (C.S.); the Department of Oncology, Santo Stefano Hospital, Azienda Unità Sanitaria Locale Toscana Centro, Prato (L.B.), and the European Institute of Oncology, IRCCS, and the Department of Oncology and Hematology-Oncology, University of Milan, Milan (G.C.) - all in Italy; the Division of Medical Oncology, Yonsei Cancer Center (J.S.), and the Department of Internal Medicine, Seoul National University Hospital (S.-A.I.) - both in Seoul, South Korea; Clinical Development, Late-Stage Development, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (N.B., G.P.); and Biometrics Oncology, Late-Stage Development, Oncology Research and Development, AstraZeneca, Waltham, MA (J.K.).
[1]
DOI
10.1056/NEJMoa2407086
PMID
39282896
发布时间
2025-01-10
换一批
换一批
